A Novel Polyaminocarboxylate Compound To Treat Murine Pulmonary Aspergillosis by Interfering with Zinc Metabolism - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2018

A Novel Polyaminocarboxylate Compound To Treat Murine Pulmonary Aspergillosis by Interfering with Zinc Metabolism

Paris Laskaris
  • Fonction : Auteur
Rocío Vicentefranqueira
  • Fonction : Auteur
Olivier Helynck
  • Fonction : Auteur
Grégory Jouvion
José Antonio Calera
  • Fonction : Auteur
Laurence Du Merle
  • Fonction : Auteur
Franck Suzenet
Frédéric Buron
Daniel Mansuy
  • Fonction : Auteur
  • PersonId : 756474
  • IdRef : 132533553
Jean-Marc Cavaillon
  • Fonction : Auteur
Jean-Paul Latgé
  • Fonction : Auteur
Hélène Munier-Lehmann
  • Fonction : Auteur
Oumaima Ibrahim-Granet
  • Fonction : Auteur

Résumé

ABSTRACT Aspergillus fumigatus can cause pulmonary aspergillosis in immunocompromised patients and is associated with a high mortality rate due to a lack of reliable treatment options. This opportunistic pathogen requires zinc in order to grow and cause disease. Novel compounds that interfere with fungal zinc metabolism may therefore be of therapeutic interest. We screened chemical libraries containing 59,223 small molecules using a resazurin assay that compared their effects on an A. fumigatus wild-type strain grown under zinc-limiting conditions and on a zinc transporter knockout strain grown under zinc-replete conditions to identify compounds affecting zinc metabolism. After a first screen, 116 molecules were selected whose inhibitory effects on fungal growth were further tested by using luminescence assays and hyphal length measurements to confirm their activity, as well as by toxicity assays on HeLa cells and mice. Six compounds were selected following a rescreening, of which two were pyrazolones, two were porphyrins, and two were polyaminocarboxylates. All three groups showed good in vitro activity, but only one of the polyaminocarboxylates was able to significantly improve the survival of immunosuppressed mice suffering from pulmonary aspergillosis. This two-tier screening approach led us to the identification of a novel small molecule with in vivo fungicidal effects and low murine toxicity that may lead to the development of new treatment options for fungal infections by administration of this compound either as a monotherapy or as part of a combination therapy.

Dates et versions

hal-03652524 , version 1 (26-04-2022)

Identifiants

Citer

Paris Laskaris, Rocío Vicentefranqueira, Olivier Helynck, Grégory Jouvion, José Antonio Calera, et al.. A Novel Polyaminocarboxylate Compound To Treat Murine Pulmonary Aspergillosis by Interfering with Zinc Metabolism. Antimicrobial Agents and Chemotherapy, 2018, 62 (6), ⟨10.1128/AAC.02510-17⟩. ⟨hal-03652524⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More